Pan-cancer mutational signature analyses have identified a signature consisting of apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC), which is a cytosine deaminase, in a subset of cancers, including HCC (Middlebrooks et al., 2016). Here, APOB is linked to cancer.